Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study.
Gardner T, Petrylak D, Corman J, Hall S, Weinstein R, Keyser R, Sims R, Sanders A, Sheikh N, Higano C. Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study. Journal Of Clinical Oncology 2013, 31: 148-148. DOI: 10.1200/jco.2013.31.6_suppl.148.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerSymptomatic metastatic castration-resistant prostate cancerMemory B cellsImmune responseOverall survivalB cellsOngoing phase 2 studyCastration-resistant prostate cancerAutologous cellular immunotherapyPeripheral immune responsePhase 2 studyProlongs overall survivalST infusionCellular immunotherapySerum antiMemory phenotypeSipuleucelPA2024Prostate cancerCSF titersActivation phenotypeAnti-GMGM-CSFFlow cytometryMature phenotype